https://www.genentech-medinfo.com/2026-03-09https://www.genentech-medinfo.com/our-products.html2026-01-20https://www.genentech-medinfo.com/our-products/cardiology.html2026-01-20https://www.genentech-medinfo.com/our-products/dermatology.html2026-01-20https://www.genentech-medinfo.com/our-products/dermatology/xolair.html2026-01-20https://www.genentech-medinfo.com/our-products/food-allergy.html2026-01-20https://www.genentech-medinfo.com/our-products/food-allergy/xolair.html2026-01-20https://www.genentech-medinfo.com/our-products/infectious-disease.html2026-01-20https://www.genentech-medinfo.com/our-products/nephrology.html2025-10-06https://www.genentech-medinfo.com/our-products/nephrology/gazyva.html2026-01-20https://www.genentech-medinfo.com/our-products/neuroscience.html2026-01-20https://www.genentech-medinfo.com/our-products/neuroscience/ocrevus.html2026-01-20OCARINA II Efficacy Datahttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/cf8c1ee5-a700-4ab6-8d84-2a28f4485d4c/d2d6b861-117a-43ca-9873-b8fe30b85ff5/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637523055911230OCARINA II Safety Datahttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/790f3530-2588-47a6-8b80-88cf08f1c76a/b08b8963-9cfa-4b04-bc1b-7440398e4d30/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637523225111266Injection Site Reactions Summaryhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/d96fc435-13e4-4132-baf4-9b0b3b2b32c0/348bb480-4495-4728-8f54-9595099af40f/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6375230775112102Deeper Dive - Injection Site Reactionshttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/97d63308-bcfc-4314-941d-af7eb65b3680/884dccda-36e1-4ebb-8fd5-fc43d9864649/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637523323611289Key Takeawayshttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/567bafa8-f860-4db5-b1f2-fb8ecba66b39/4cc77e2e-d634-463d-ac6e-01ba3d382e11/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637523088111279OCARINA II Label Overviewhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/e36ab4b2-fe38-45eb-bbf7-a89787f573cf/517d1266-f213-4758-b703-b80edd96fda4/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637523224611293OCARINA II Recombinant Human Hyaluronidasehttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/b25c0c26-8ef7-4ec6-9757-c123ed28d6fc/5cc2369e-8121-410e-b3b4-5242d03f8b31/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637523055011262OCARINA II Pharmacokinetic Bridging Designhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/6c3ff5e8-f8f0-43e3-95bd-cecaa9ab775a/9179ef82-1799-4f55-9264-78dee1a5c077/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637523183711241OCARINA II Studyhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/3c427ef4-e024-4ba5-abd9-943bd7a35b8b/c89fa30a-0f41-48e9-8ed5-529234f7ebaf/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6375233030112197https://www.genentech-medinfo.com/our-products/neuroscience/ocrevus/pregnancy-and-lactation.html2026-01-20https://www.genentech-medinfo.com/our-products/neuroscience/ocrevus/administration-related-adverse-events.html2026-01-20https://www.genentech-medinfo.com/our-products/neuroscience/all-neuroscience-products.html2022-08-18https://www.genentech-medinfo.com/our-products/oncology.html2026-01-20https://www.genentech-medinfo.com/our-products/oncology/alecensa.html2026-02-20https://www.genentech-medinfo.com/our-products/oncology/columvi.html2026-01-20https://www.genentech-medinfo.com/our-products/oncology/itovebi.html2026-01-20Itovebi Introduction, Disclaimer, Indication and Dosinghttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/69078ffd-b9cf-4df9-ba5b-5ebac1f5a84c/b61f6e60-4756-44e6-914b-62ca05f886da/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6384704220112177INAVO120 Overviewhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/ab48e04b-6e53-4dd7-a7e3-05c4093869de/65a6735f-5bb6-4254-8fd8-0933b92dc8a0/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6384693650112260INAVO120 Efficacy & Safetyhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/5dd98983-938b-4089-847d-356eb174b57c/31081522-7899-470c-b54b-8f53527bf3fc/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6384696947112751Itovebi Phase 1 G039374 Safetyhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/08c0cb5d-4dee-463b-9750-90600e640f13/d814acce-5321-4134-bbad-9c9d19f1ca24/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6384699248112647Itovebi Adverse Event Management for Hyperglycemiahttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/9a1447fd-3e36-48cc-8916-83e2b421a7a7/8bedc780-356d-4555-ab65-d3af5fb55530/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6384709083112602https://www.genentech-medinfo.com/our-products/oncology/lunsumio.html2026-01-20https://www.genentech-medinfo.com/our-products/oncology/polivy.html2026-01-20Dosage and Administrationhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/c58058db-4bba-4880-b87b-0f79f146e854/be76e24e-bac3-4139-b5ba-c1ce3f8af1d1/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637132738611265Management of Peripheral Neuropathyhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/b74941df-e59b-455e-8153-ab68640c0faf/e56cdee2-2ccc-41f2-a4b3-c2a59cf653dc/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6371326297112214Introduction and Reporting Adverse Eventshttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/b090d1de-6191-4f1b-a12b-bb7d4a85c5d5/0d23b53c-076f-40fb-93f2-8adf4c87b493/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637132828211268Indications and Usagehttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/e358dcf4-d3bb-40a4-b890-60be582d3dc4/fd66d4fe-49e1-42cf-a787-d72664947268/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637132581711262Polarix Study Design and Endpointshttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/179878a8-112d-4ae1-b9e4-23793968ac60/e2676ec9-709b-4339-95a7-6a35d33307c7/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6371327987112122Difference Between ITT and FDA Approved Indicationhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/c9cd27ba-32db-4688-b14a-eb8d360b34dd/8cdbba57-3817-44f4-8d6a-5c40cded1ae9/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637132837511290Efficacy and Safety Profilehttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/8c8819a6-badf-435f-9da9-30c30d79a503/21098cf6-b187-49df-b8a1-b0f7b2c5c320/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6371326405112398https://www.genentech-medinfo.com/our-products/oncology/tecentriq.html2026-01-20Tecentriq® Mechanism of Actionhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/d365e3a8-07de-4f1e-ac1c-52b1f6f9ee7f/0877f66e-f260-46fb-b6f3-46556358c63b/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6319374037112193Tecentriq® Mechanism of Actionhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/d365e3a8-07de-4f1e-ac1c-52b1f6f9ee7f/0877f66e-f260-46fb-b6f3-46556358c63b/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6319374037112193https://www.genentech-medinfo.com/our-products/oncology/venclexta.html2026-03-23https://www.genentech-medinfo.com/our-products/oncology/all-oncology-products.html2022-08-18https://www.genentech-medinfo.com/our-products/ophthalmology.html2026-01-20https://www.genentech-medinfo.com/our-products/ophthalmology/lucentis.html2026-01-20https://www.genentech-medinfo.com/our-products/ophthalmology/susvimo.html2026-01-20Port Delivery System with Ranibizumab (PDS) Implant Insertion Procedure

An overview of the PDS implant insertion procedure

]]>https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/b207d3a9-724f-43a4-918e-f78911c59e33/7d6073ff-3477-44de-ba73-9ab21b3e9c77/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6310298002112352Port Delivery System with Ranibizumab (PDS) Refill-Exchange Procedure

An overview of the steps for the PDS refill-exchange procedure

]]>https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/df03580d-edff-4f9a-8ce4-f80f402faaf0/4f0edfed-2c8c-4844-8186-decb831f0bd6/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6312982374112308https://www.genentech-medinfo.com/our-products/ophthalmology/vabysmo.html2026-01-20https://www.genentech-medinfo.com/our-products/ophthalmology/all-ophthalmology-products.html2022-08-18https://www.genentech-medinfo.com/our-products/rare-blood-disorders.html2026-01-20https://www.genentech-medinfo.com/our-products/rare-blood-disorders/hemlibra.html2026-01-20https://www.genentech-medinfo.com/our-products/rare-blood-disorders/piasky.html2026-01-20https://www.genentech-medinfo.com/our-products/rare-blood-disorders/all-rare-blood-disorders-products.html2024-05-13https://www.genentech-medinfo.com/our-products/respiratory.html2026-01-20https://www.genentech-medinfo.com/our-products/respiratory/xolair.html2026-01-20https://www.genentech-medinfo.com/our-products/respiratory/all-respiratory-products.html2024-01-25https://www.genentech-medinfo.com/our-products/rheumatology.html2026-01-23https://www.genentech-medinfo.com/our-products/rheumatology/gazyva.html2026-01-20https://www.genentech-medinfo.com/our-products/rheumatology/all-rheumatology-products.html2025-10-01https://www.genentech-medinfo.com/our-products/view-all-products.html2022-08-18https://www.genentech-medinfo.com/pipeline-and-clinical-trials.html2026-03-09https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm.html2026-02-13https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/ct-388.html2026-01-26https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/ct-388/phase-ii-ct-388-in-obesity-ct-388-103.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/ct-388/phase-ii-ct-388-in-obesity-with-type-2-diabetes-mellitus-ct-388-104.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/ct-996.html2026-01-26https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/ct-996/phase-ii-ct-996-in-obesity-or-overweight-study-bp45702.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/emugrobart.html2026-02-16https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/emugrobart/phase-ii-emugrobart-for-overweight-obesity-gyminda-study.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/pegozafermin.html2026-03-03https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/pegozafermin/phase-iii-pegozafermin-in-severe-hypertriglyceridemia-entrust.html2026-01-26https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/pegozafermin/phase-iii-pegozafermin-in-mash-and-fibrosis-enlighten-fibrosis.html2026-01-26https://www.genentech-medinfo.com/pipeline-and-clinical-trials/cvrm/pegozafermin/phase-iii-pegozafermin-in-mash-with-compensated-cirrhosis-enlighten-cirrhosis.html2026-01-26https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology.html2026-02-17https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology/afimkibart.html2026-03-02https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology/afimkibart/phase-iii-afimkibart-in-uc-ametrine1.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology/afimkibart/phase-iii-afimkibart-in-uc-ametrine2.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology/afimkibart/phase-iii-afimkibart-in-cd-siberite1.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology/afimkibart/phase-iii-afimkibart-in-cd-siberite2.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology/sefaxersen.html2026-02-18https://www.genentech-medinfo.com/pipeline-and-clinical-trials/immunology/sefaxersen/phase-iii-sefaxersen-in-primary-iga-nephropathy-imagination.html2026-03-05https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology.html2026-02-06https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/divarasib.html2026-02-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/divarasib/phase-iii-divarasib-in-metastatic-nsclc-krascendo1.html2026-02-03https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/divarasib/phase-iii-divarasib-and-pembrolizumab-in-nsclc-krascendo2.html2026-01-27https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/giredestrant.html2026-01-23https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/giredestrant/phase-iii-giredestrant-in-bc-pionera.html2026-01-23pionERA Breast Cancer Clinical Trial Recruitment: Dr. Kevin KalinskyDr. Kevin Kalinsky speaks about the pionERA Breast Cancer clinical trial, eligibility criteria and the importance of early enrollment.https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/0bf40fe3-509e-4ae1-a6ed-616287fc0f9a/3b45a143-ef57-4740-bc22-c51f4b847ba2/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6375729498112247https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/glofitamab.html2026-03-02https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/glofitamab/phase-iii-glofitamab-in-1l-lbcl-skyglo.html2026-03-02https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/inavolisib.html2026-01-27https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/inavolisib/phase-iii-inavolisib-in-breast-cancer-inavo122.html2026-01-23https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/inavolisib/phase-iii-inavolisib-in-breast-cancer-inavo123.html2026-01-27https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/emicizumab.html2026-02-06https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/emicizumab/observational-study-in-type-3-vwd-will-emi-nis.html2026-02-06https://www.genentech-medinfo.com/pipeline-and-clinical-trials/oncology/emicizumab/phase-iii-emicizumab-in-type-3-vwd-will-emi.html2026-02-13https://www.genentech-medinfo.com/pipeline-and-clinical-trials/ophthalmology.html2025-11-25https://www.genentech-medinfo.com/pipeline-and-clinical-trials/ophthalmology/ranibizumab.html2026-01-28https://www.genentech-medinfo.com/pipeline-and-clinical-trials/ophthalmology/ranibizumab/phase-iv-port-delivery-system-with-ranibizumab-in-namd-belvedere.html2026-02-19https://www.genentech-medinfo.com/disease-state-information.html2026-01-20https://www.genentech-medinfo.com/disease-state-information/food-allergy.html2026-01-20https://www.genentech-medinfo.com/disease-state-information/neuroscience.html2026-01-20https://www.genentech-medinfo.com/disease-state-information/neuroscience/pregnancy-and-lactation-in-patients-with-multiple-sclerosis.html2025-11-21https://www.genentech-medinfo.com/disease-state-information/neuroscience/health-equity-in-multiple-sclerosis.html2025-11-21https://www.genentech-medinfo.com/disease-state-information/neuroscience/immunoglobulins-in-patients-with-multiple-sclerosis.html2025-11-21https://www.genentech-medinfo.com/disease-state-information/oncology.html2026-01-20https://www.genentech-medinfo.com/disease-state-information/oncology/cancer-immunology.html2025-11-21https://www.genentech-medinfo.com/disease-state-information/oncology/bispecific-antibodies.html2025-11-21https://www.genentech-medinfo.com/disease-state-information/oncology/biomarker-testing.html2025-12-08https://www.genentech-medinfo.com/disease-state-information/oncology/cytokine-release-syndrome.html2025-11-21https://www.genentech-medinfo.com/disease-state-information/food-allergy-spanish.html2026-01-20https://www.genentech-medinfo.com/disease-state-information/food-allergy-chinese.html2026-01-20https://www.genentech-medinfo.com/disease-state-information/food-allergy-arabic.html2026-01-20https://www.genentech-medinfo.com/conferences.html2026-01-20https://www.genentech-medinfo.com/conferences/ibd.html2026-03-09IBD Afimkibart Proposed MOAhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/337f108d-3c65-45f7-8d73-41a1d0a73956/5ae89871-4a6b-4b23-9a73-35272fa6f6e4/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=6385414830112100https://www.genentech-medinfo.com/conferences/lymphoma.html2025-12-15https://www.genentech-medinfo.com/conferences/lymphoma/publications.html2026-01-20https://www.genentech-medinfo.com/conferences/other-therapeutic-areas.html2025-11-24https://www.genentech-medinfo.com/resources.html2026-01-20https://www.genentech-medinfo.com/resources/contact-an-msl.html2026-01-20https://www.genentech-medinfo.com/resources/submit-medical-inquiry.html2026-01-20https://www.genentech-medinfo.com/resources/stability-calculator.html2026-01-20https://www.genentech-medinfo.com/resources/resources.html2026-01-20https://www.genentech-medinfo.com/resources/genentech-medical-linkedin-community-guidelines.html2026-01-20https://www.genentech-medinfo.com/resources/genentech-medical-twitter-community-guidelines.html2026-01-20https://www.genentech-medinfo.com/fenebrutinib.html2026-01-20Proposed MOA of Fenebrutinibhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/0f4c033a-5151-4f2f-b4e9-f57306834583/c3b7ab86-a501-4656-b8ae-f49d9e8c9c31/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637680601311265Role of BTKhttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/890c15aa-c306-4731-9cb9-5fd4e969c04e/73c42d7b-23e7-42c8-b523-026329d4560d/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637680445311263Pathophysiology of MShttps://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/5c02711e-be20-41f2-abec-46a80589d494/d508ac8f-1ddc-4002-849f-9d761e55d9bb/231x130/match/image.jpghttps://players.brightcove.net/6125588073001/3cfaAcUC_default/index.html?videoId=637680524411287https://www.genentech-medinfo.com/search.html2025-12-16https://www.genentech-medinfo.com/sitemap.html2025-08-08https://www.genentech-medinfo.com/404.html2025-08-08https://www.genentech-medinfo.com/500.html2025-08-08